Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients

Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):e137-e143. doi: 10.1016/j.clml.2019.12.022. Epub 2020 Jan 8.

¹ Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL. Electronic address: [email protected].
² Department of Pathology, Cleveland Clinic Florida, Weston, FL.
³ Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL.
⁴ The John Conant Davis Myeloma and Amyloid Program, Division of Hematology-Oncology, Tufts Medical Center, Boston, MA.
⁵ Multiple Myeloma Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.
⁶ Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Keywords: Amyloidosis; Daratumumab; Multiple myeloma; Plasmacytic post-transplant lymphoproliferative disorder; Solid organ transplant.

Publication types